iBio Business Summary

iBio, Inc. (IBIO) is an AI-driven biotechnology company specializing in the discovery and development of precision antibody therapies for cardiometabolic diseases and obesity. The company generates revenue primarily through strategic licensing agreements, research collaborations, and potential future milestone payments, having recently pivoted from its legacy contract development and manufacturing (CDMO) services to focus on its proprietary AI Drug Discovery Platform. This platform leverages 3D modeling and epitope-steering to target complex proteins like Activin E and Myostatin. iBio operates through two primary segments: Biopharmaceuticals, which houses its preclinical pipeline (including lead candidates IBIO-610 and IBIO-600), and Bioprocessing, which utilizes its plant-based FastPharming System. Direct competitors include Arcturus Therapeutics, Alector, C4 Therapeutics, and Tharimmune; iBio distinguishes itself as a high-density preclinical innovator utilizing computational biology to address the massive total addressable market for next-generation weight-loss and metabolic therapies. Originally founded in 2008 by Robert B. Kay and Robert L. Erwin, the company is currently led by Chief Executive Officer and Chief Scientific Officer Martin Brenner, Ph.D., DVM, who brings a distinguished pedigree from leadership roles at Pfizer, Merck, AstraZeneca, and Eli Lilly, as well as serving as CSO of Pfenex Inc. through its $516 million acquisition by Ligand Pharmaceuticals. The executive team is rounded out by Chief Financial Officer Felipe Duran, formerly of Lupin Pharmaceuticals, and Chief Legal Officer Marc Banjak. The company’s strategic direction is overseen by a board chaired by Chip Clark and includes industry veterans like Alexandra Kropotova and David Arkowitz. iBio is backed by notable institutional investors, most recently securing a $26 million PIPE financing in January 2026 led by Frazier Life Sciences to fund its transition into human clinical trials.